Board Changes

Board Changes

Porton Down, UK; 5 April 2012: GW Pharmaceuticals plc (AIM: GWP) announces that, after ten years as Finance Director, David Kirk has informed the Company that he intends to stand down from the Board on 1st June 2012. David will be succeeded by Adam David George, aged 42, who has served as GW's Company Secretary and Group Financial Controller since 2007 and will take on the role of Finance Director and join the Board on 1st June 2012. David will continue to be available to the Company in a consulting capacity for an agreed period of time.

In addition, in view of the expansion of the Group's operations since the launch of Sativex, the Board has also decided that it intends to add a new executive role of Chief Operating Officer to the Board. A search for this new position has recently commenced.

Adam George joined GW in 2007 and, as Group Financial Controller and Company Secretary, has played a significant role alongside the Executive Directors of the Company in all aspects of GW's business and has been increasingly responsible for GW's day to day financial management. Prior to joining GW, Adam occupied several senior finance roles within both listed and privately owned high growth businesses. From 2004 to 2007, Adam was Finance Director of Believe It Group Limited (now 4Com plc), a telecommunications service provider, having been Group Financial Controller from 2001 to 2004. From 1997 to 2000, he was Group Financial Controller at Helphire Group plc, and prior to this was Group Financial Accountant at Allied Domecq plc. Adam qualified as a chartered accountant in 1995, having trained with Price Waterhouse Coopers, and holds a B.Sc. in Biology from Bristol University.

Dr Geoffrey Guy, Chairman, said, "David has been Finance Director of GW for over ten years and played an instrumental role in successfully steering the Group's finances over this long period. David can be rightfully proud to be leaving GW in its strongest financial position to date. The Board thanks him for his very significant contribution to GW and wishes him well for the future. We are delighted to have in Adam George a well-qualified internal successor to David and look forward to welcoming Adam as a member of the Board."

The following disclosures are made in accordance with AIM rule 17 and Schedule 2 paragraph (g) of the AIM rules:

Adam George holds a beneficial interest in 21,696 GW Pharmaceuticals 0.1 pence ordinary shares.

Adam George is currently a Director of the following companies:

GW Pharma Limited

GW Research Limited

G-Pharm Limited

GWP Trustee Company Limited

G-Pharm Trustee Company Limited

Cannabinoid Research Institute Limited

GWZ Research Limited

Finance Direction Limited

Prior to joining GW in 2007, Adam George was formerly a Director of the following companies:

Believe It Group Limited

4Com Limited

4Com Networks Limited

Believe It Communications Group Limited

Pioneer Business Systems Limited

Seeing is Believing Limited

Enquiries:

Notes to Editors

About GW

GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including development and regulatory clearance of the GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals.